image
Healthcare - Biotechnology - NASDAQ - US
$ 236.75
-0.772 %
$ 30.8 B
Market Cap
-106.28
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALNY stock under the worst case scenario is HIDDEN Compared to the current market price of 237 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALNY stock under the base case scenario is HIDDEN Compared to the current market price of 237 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ALNY stock under the best case scenario is HIDDEN Compared to the current market price of 237 USD, Alnylam Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ALNY

image
$300.0$300.0$290.0$290.0$280.0$280.0$270.0$270.0$260.0$260.0$250.0$250.0$240.0$240.0$230.0$230.0$220.0$220.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.25 B REVENUE
22.97%
-177 M OPERATING INCOME
37.31%
-278 M NET INCOME
36.82%
-8.31 M OPERATING CASH FLOW
-7.98%
-117 M INVESTING CASH FLOW
65.26%
294 M FINANCING CASH FLOW
70.89%
593 M REVENUE
18.42%
-105 M OPERATING INCOME
-36.74%
-83.8 M NET INCOME
24.92%
-94.7 M OPERATING CASH FLOW
-216.58%
-52.9 M INVESTING CASH FLOW
-74.91%
31 M FINANCING CASH FLOW
-69.83%
Balance Sheet Alnylam Pharmaceuticals, Inc.
image
Current Assets 3.3 B
Cash & Short-Term Investments 2.69 B
Receivables 405 M
Other Current Assets 195 M
Non-Current Assets 945 M
Long-Term Investments 0
PP&E 694 M
Other Non-Current Assets 251 M
63.55 %9.56 %4.61 %16.37 %5.91 %Total Assets$4.2b
Current Liabilities 1.19 B
Accounts Payable 88.4 M
Short-Term Debt 41.9 M
Other Current Liabilities 1.06 B
Non-Current Liabilities 2.99 B
Long-Term Debt 0
Other Non-Current Liabilities 2.99 B
25.31 %71.57 %Total Liabilities$4.2b
EFFICIENCY
Earnings Waterfall Alnylam Pharmaceuticals, Inc.
image
Revenue 2.25 B
Cost Of Revenue 323 M
Gross Profit 1.92 B
Operating Expenses 2.1 B
Operating Income -177 M
Other Expenses 101 M
Net Income -278 M
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)2b(323m)2b(2b)(177m)(101m)(278m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.62% GROSS MARGIN
85.62%
-7.87% OPERATING MARGIN
-7.87%
-12.37% NET MARGIN
-12.37%
-414.62% ROE
-414.62%
-6.56% ROA
-6.56%
-8.88% ROIC
-8.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alnylam Pharmaceuticals, Inc.
image
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)(800m)(800m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -278 M
Depreciation & Amortization 56.7 M
Capital Expenditures -34.3 M
Stock-Based Compensation 272 M
Change in Working Capital 0
Others 47.9 M
Free Cash Flow -42.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Alnylam Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ALNY of $304 , with forecasts ranging from a low of $235 to a high of $400 .
ALNY Lowest Price Target Wall Street Target
235 USD -0.74%
ALNY Average Price Target Wall Street Target
304 USD 28.45%
ALNY Highest Price Target Wall Street Target
400 USD 68.95%
Price
Max Price Target
Min Price Target
Average Price Target
400400350350300300250250200200150150100100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Alnylam Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
11 M USD 6
3-6 MONTHS
21.8 M USD 6
6-9 MONTHS
19.6 M USD 3
9-12 MONTHS
17.7 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the. businesswire.com - 2 weeks ago
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com - 3 weeks ago
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. businesswire.com - 1 month ago
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois. businesswire.com - 1 month ago
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds. businesswire.com - 1 month ago
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering. globenewswire.com - 1 month ago
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran). benzinga.com - 1 month ago
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com - 1 month ago
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. seekingalpha.com - 1 month ago
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy. zacks.com - 1 month ago
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. benzinga.com - 1 month ago
Alnylam shares rise on expanded heart drug approval Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's blockbuster Vyndaqel. reuters.com - 1 month ago
8. Profile Summary

Alnylam Pharmaceuticals, Inc. ALNY

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 30.8 B
Dividend Yield 0.00%
Description Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Contact 675 West Kendall Street, Cambridge, MA, 02142 https://www.alnylam.com
IPO Date June 1, 2004
Employees 2230
Officers Mr. Jeffrey V. Poulton M.B.A. Chief Financial Officer & Executive Vice President Mr. Timothy J. Maines Chief Technical Operations & Quality Officer Mr. Robert W. Hesslein Esq., J.D. Executive Vice President, Chief Legal Officer & Corporate Secretary Ms. Christine Regan Lindenboom Chief Corporate Communications Officer Dr. Phillip A. Sharp Ph.D. Co-Founder, Member of the Scientific Advisory Board & Independent Director Mr. Piyush Sharma J.D. Chief Ethics & Compliance Officer Dr. Pushkal P. Garg M.D. Chief Medical Officer and Executive Vice President of Development & Medical Affairs Dr. Yvonne L. Greenstreet M.B.A., M.D. Chief Executive Officer & Director Dr. Kevin Joseph Fitzgerald Ph.D. Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development Mr. Tolga Tanguler M.B.A. Executive Vice President & Chief Commercial Officer